Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial in patients with multiple myeloma to optimize bortezomib based induction (bortezomib, Adriamycin, dexamethasone [PAd] vs. bortezomib, cyclophosphamide, dexamethasone [VCD]) prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide based consolidation and maintenance therapy.

Next Previous
Search
Trial Profile

Phase III trial in patients with multiple myeloma to optimize bortezomib based induction (bortezomib, Adriamycin, dexamethasone [PAd] vs. bortezomib, cyclophosphamide, dexamethasone [VCD]) prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide based consolidation and maintenance therapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Lenalidomide; Melphalan
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms MM5

    • Most Recent Events

    • 13 Dec 2022 Results defining implications and prognostic value of MS in a large cohort of transplant eligible patients with newly diagnosed MM treated within the phase 3 multicenter GMMG MM5 trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 14 Dec 2021 Results of Intergroup Analysis from phase III trials, HD4, MM5 and HD6 and European Myeloma Network (EMN) 02/ Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation (HOVON) 95 presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 01 Mar 2021 Results of an exploratory subgroup analysis with focus on progression free survival (PFS), overall survival (OS), time to progression (TTP), non relapse mortality (NRM), response rates and toxicities with regard to patient age at randomization published in the Leukemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top